JLHL279.00

Jupiter Life Line Hospitals Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPMAXHEALTHKIMSHCGMARKSANSMETROPOLISPARKHOSPSCORONAMcap ₹1,829 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
JLHL
FY26
APOLLOHOSP
FY26
MAXHEALTH
FY26
KIMS
FY26
Peer
Median
Valuation — at last close
P/E9.43×65.86×69.66×128.36×69.66× -86%
P/B1.18×12.82×9.36×12.10×12.10× -90%
EV/EBITDA5.24×34.95×46.08×42.56×42.56× -88%
Market Cap₹1,829 Cr₹1.28L Cr₹1.01L Cr₹30,960 Cr₹1.01L Cr -98%
Growth
Revenue CAGR 3Y18.89%14.94%22.43%21.12%21.12% -11%
Revenue CAGR 5Y19.03%27.30%24.04%24.04%
Net Income CAGR 3Y39.77%33.35%9.34%-12.87%9.34% +326%
Revenue YoY (latest Q)18.23%20.56%16.70%35.33%20.56% -11%
Net Income YoY (latest Q)-14.50%38.41%4.87%-56.00%4.87% -398%
Profitability
EBITDA Margin22.89%14.94%26.79%20.54%20.54% +11%
Net Income Margin13.27%7.94%17.23%6.20%7.94% +67%
Return on Common Equity12.59%19.47%13.42%9.44%13.42% -6%
Return on Capital Employed11.85%18.41%11.94%7.96%11.94% -1%
Return on Assets8.35%9.02%8.37%3.12%8.37% -0%
Credit & Quality
Total Debt/Equity0.33×0.57×0.32×1.27×0.57× -42%
Interest Coverage7.83×6.44×7.64×2.56×6.44× +22%
Scale — latest FY
Revenue / Total Income₹1,500 Cr₹25,229 Cr₹8,373 Cr₹3,905 Cr₹8,373 Cr -82%
Net Income₹199 Cr₹2,003 Cr₹1,442 Cr₹242 Cr₹1,442 Cr -86%
Total Assets₹2,383 Cr₹22,197 Cr₹17,231 Cr₹7,759 Cr₹17,231 Cr -86%
EPS₹29.59₹135.04₹14.83₹6.03₹14.83 +100%
Book Value per Share₹235.5₹693.64₹110.43₹63.96₹110.43 +113%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.